Improved quality of life

SPIOLTO® RESPIMAT® provides significant improvements in quality of life vs SPIRIVA® and placebo in patients with moderate to severe COPD. Improvements were even more apparent in patients with GOLD B COPD.

SPIOLTO® RESPIMAT® provides a clinically meaningful 4-point* quality of life improvement vs placebo in St. George’s Respiratory Questionnaire (SGRQ) total score.1,2
 

Domains of SGRQ included:3

  • Activities

  • Impact

  • Symptoms

SGRQ Total score after 12 weeks in patients at GOLD 21

SGRQ-Total-score-after-12-weeks

Adapted from reference 1

SPIOLTO® RESPIMAT® improves quality of life in GOLD B patients

The benefits of SPIOLTO® RESPIMAT® vs SPIRIVA® on quality of life were most apparent in GOLD B patients.1,4
 

Improvement in SGRQ total score at 12 weeks between SPIOLTO® RESPIMAT® and SPIRIVA® in patients with GOLD A-D COPD

Adapted from reference 1

References

  1. Singh D et al. Resp Res 2016;17(73):1-13 and supplementary information.
  2. Singh D, et al. Respir Med. 2015;109:1312-1319.
  3. Jones PW. SGRQ Manual Version 2.3. June 2009.
  4. Boehringer Ingleheim. Data on file.